Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 133,590 shares, a growth of 2,380.8% from the December 31st total of 5,385 shares. Based on an average daily volume of 2,064,105 shares, the short-interest ratio is currently 0.1 days. Approximately 8.4% of the company’s shares are short sold. Approximately 8.4% of the company’s shares are short sold. Based on an average daily volume of 2,064,105 shares, the short-interest ratio is currently 0.1 days.

Cardio Diagnostics Stock Performance

Shares of NASDAQ CDIO traded up $0.03 during mid-day trading on Tuesday, reaching $1.84. The company had a trading volume of 49,675 shares, compared to its average volume of 1,143,069. The company has a market capitalization of $3.37 million, a price-to-earnings ratio of -0.49 and a beta of 2.94. The stock has a fifty day moving average of $2.77 and a two-hundred day moving average of $3.56. Cardio Diagnostics has a 12-month low of $1.64 and a 12-month high of $20.55.

Cardio Diagnostics (NASDAQ:CDIO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.80) by $0.82. Cardio Diagnostics had a negative net margin of 39,674.18% and a negative return on equity of 67.51%. The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.15 million. Sell-side analysts forecast that Cardio Diagnostics will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardio Diagnostics in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Trading of Cardio Diagnostics

An institutional investor recently bought a new position in Cardio Diagnostics stock. Citadel Advisors LLC acquired a new stake in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned about 1.07% of Cardio Diagnostics at the end of the most recent quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.